Exploring a biomarker for phenotypic variants of TB to map antimicrobial response

Project Summary 

Treatment of tuberculosis is long (≥6 months) and requires a combination of drugs. Scientists have been trying to develop more effective drug combinations although this is not straightforward.

Deciding on the best combination and amount of drugs for tuberculosis treatment when they are given in combination remains challenging. This project aims to investigate biomarkers for phenotypic variants of tuberculosis to apply them for the characterization and quantification of detailed antimicrobial responses for drug combinations. This can ultimately aid the optimization of anti-tubercular treatment.

Links to other research

Other research from the UCL Centre for Pragmatic Global Health Trials

Other research from IGH on Pharmacology, Modelling, Statistics and Translational Research

Other research from IGH in the UK

Project information

Dates: 01/04/2021 - 31/03/2024

Status: Current

UCL lead/Principal Investigator: Frank Kloprogge, UCL Institute for Global Health

IGH lead: Frank Kloprogge

Funding: Wellcome Trust

Contact: f.kloprogge@ucl.ac.uk 

Research team

Arundhati Maitra